{"id":"https://openalex.org/W2618269652","doi":"https://doi.org/10.1182/blood.v128.22.5126.5126","title":"Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents","display_name":"Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2618269652","doi":"https://doi.org/10.1182/blood.v128.22.5126.5126","mag":"2618269652"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.5126.5126","doi":"https://doi.org/10.1182/blood.v128.22.5126.5126","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.5126.5126","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072602077","display_name":"Carter Thomas Davis","orcid":"https://orcid.org/0000-0001-8128-5340","observed_orcids":["https://orcid.org/0000-0001-8128-5340"]},"institutions":[{"id":"https://openalex.org/I4210144876","display_name":"Duke University Health System","ror":"https://ror.org/03wfqwh68","country_code":"US","type":"education","lineage":["https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carter Thomas Davis","raw_affiliation_strings":["Duke University Health System, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Health System, Durham, NC","institution_ids":["https://openalex.org/I4210144876"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056698355","display_name":"Arati V. Rao","orcid":"https://orcid.org/0009-0004-2922-710X","observed_orcids":["https://orcid.org/0009-0004-2922-710X"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arati V. Rao","raw_affiliation_strings":["Duke Cancer Institute, Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke Cancer Institute, Duke University, Durham, NC","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086342513","display_name":"Eross Guadalupe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eross Guadalupe","raw_affiliation_strings":["Duke University Medical Center, Durham,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham,","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111673693","display_name":"Dale J. Christensen","orcid":"https://orcid.org/0009-0007-6013-0770","observed_orcids":["https://orcid.org/0009-0007-6013-0770","https://orcid.org/0000-0003-3815-6839"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dale J. Christensen","raw_affiliation_strings":["Duke University Medical Center, Department of Medicine, Division of Hematology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Department of Medicine, Division of Hematology, Durham, NC","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102751703","display_name":"Joe Brice Weinberg","orcid":"https://orcid.org/0000-0003-4052-5576","observed_orcids":["https://orcid.org/0000-0003-4052-5576"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Brice Weinberg","raw_affiliation_strings":["Duke University Medical Center, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC","institution_ids":["https://openalex.org/I4210126298"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5086342513","https://openalex.org/A5111673693"],"corresponding_institution_ids":["https://openalex.org/I4210126298"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.20370431,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"128","issue":"22","first_page":"5126","last_page":"5126"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11308","display_name":"Sphingolipid Metabolism and Signaling","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fingolimod","display_name":"fingolimod","score":0.9800000190734863},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9459999799728394},{"id":"https://openalex.org/keywords/protein-phosphatase-2a","display_name":"protein phosphatase 2A","score":0.8960000276565552},{"id":"https://openalex.org/keywords/sphingosine-1-phosphate-receptor-agonist","display_name":"sphingosine-1-phosphate receptor agonist","score":0.8830000162124634},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.7570000290870667},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.550000011920929},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.7390000224113464},{"id":"https://openalex.org/keywords/idarubicin","display_name":"idarubicin","score":0.9800000190734863},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9869999885559082},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.3499999940395355}],"concepts":[{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7111523747444153},{"id":"https://openalex.org/C2776036978","wikidata":"https://www.wikidata.org/wiki/Q425137","display_name":"Fingolimod","level":3,"score":0.6474058032035828},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.594247043132782},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5750446319580078},{"id":"https://openalex.org/C2775934118","wikidata":"https://www.wikidata.org/wiki/Q424169","display_name":"Propidium iodide","level":4,"score":0.535615086555481},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.5340365767478943},{"id":"https://openalex.org/C2779117419","wikidata":"https://www.wikidata.org/wiki/Q1063862","display_name":"Idarubicin","level":4,"score":0.5205603241920471},{"id":"https://openalex.org/C2781021840","wikidata":"https://www.wikidata.org/wiki/Q411659","display_name":"Daunorubicin","level":3,"score":0.4663158357143402},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.43578803539276123},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4247666001319885},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35369062423706055},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3404044508934021},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.23355627059936523},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20381540060043335},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.12395542860031128},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.10249841213226318},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.08058291673660278},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.5126.5126","doi":"https://doi.org/10.1182/blood.v128.22.5126.5126","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.5126.5126","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2978386692","https://openalex.org/W2334359151","https://openalex.org/W1968076808","https://openalex.org/W7099437857","https://openalex.org/W3000635934","https://openalex.org/W2526339802","https://openalex.org/W7125526203","https://openalex.org/W2071183768","https://openalex.org/W2952613983","https://openalex.org/W2590429097"],"abstract_inverted_index":{"Abstract":[0],"INTRODUCTION:":[1],"Conventional":[2],"treatment":[3],"of":[4,42,58,107,148,162,186,199,201,217,232,253,273,297,317,322,341,385,450,474,507,509,571,582,655,665,676,687],"acute":[5],"myeloid":[6],"leukemia":[7],"(AML)":[8],"remains":[9],"largely":[10],"unchanged":[11],"for":[12,38,84,215,363,406,602,646],"over":[13,515],"thirty":[14],"years.":[15],"With":[16],"poor":[17],"overall":[18],"survival":[19,62],"and":[20,53,63,117,119,139,193,227,242,244,261,325,343,392,514,604,614,642],"disease":[21],"cure":[22],"rates,":[23],"novel":[24],"therapies":[25],"are":[26],"needed.":[27],"The":[28,303,466],"SET":[29,52,124,233,543,554,562,591,612,629,641],"oncoprotein":[30],"has":[31,68,95,532],"been":[32,69,494,558],"implicated":[33],"in":[34,76,110,126,169,257,349,444,481,490,519,546,575,584,593,622,632,649,657,667,679,690],"AML":[35,111,127,254,350,414,547],"as":[36,143,145,183,454,477,483,644],"essential":[37],"proliferation":[39,64],"through":[40,151],"inhibition":[41],"the":[43,265,271,282,288,354,358,402,412,417,425,436,472,505,535,580,628],"tumor":[44,551],"suppressor":[45],"protein":[46],"phosphatase":[47],"2A":[48],"(PP2A).":[49],"Interaction":[50],"between":[51],"PP2A":[54,67,643],"leads":[55],"to":[56,71,98,275,290,397,471,496,610,617,625],"inactivation":[57],"PP2A,":[59],"leaving":[60],"cell":[61,115,128,141,259,267,284,326,356,404,415,524],"signals":[65],"unchecked.":[66],"postulated":[70],"be":[72,276,291,527,569,608],"an":[73,80,152,478],"important":[74],"target":[75],"AML.":[77,445,576,594,633,650],"Fingolimod":[78],"(FTY720),":[79],"FDA":[81],"approved":[82],"drug":[83,480,647],"relapsing-remitting":[85],"multiple":[86,491],"sclerosis,":[87],"is":[88,440,448,502,511,517],"a":[89,184,329,398,441,573,598],"sphingosine-1":[90],"phosphate":[91],"receptor":[92],"agonist":[93],"that":[94,438,504,606,636],"off-target":[96],"activity":[97,581],"activate":[99],"PP2A.":[100],"In":[101,264,281,294,353,375,411,422,549],"this":[102,475],"work,":[103],"we":[104,235,269,286,299,615],"show":[105],"evidence":[106],"FTY720's":[108],"efficacy":[109],"cells":[112,173,202,255,586,659,669],"derived":[113],"from":[114,486],"lines":[116,260],"patients,":[118],"provide":[120],"preliminary":[121],"data":[122,434],"regarding":[123],"expression":[125,592],"lines.":[129],"METHODS:":[130],"Cytotoxicity":[131,653,663],"experiments":[132,214,624,638],"were":[133,156,174,219,336,361,464],"performed":[134,221,236],"using":[135,206],"HL-60,":[136],"THP-1,":[137],"MV-4,":[138],"Kasumi-3":[140,423],"lines,":[142],"well":[144],"patient-derived":[146,262,295],"samples":[147,296,319,620],"AML,":[149,298,482],"obtained":[150],"IRB-approved":[153],"protocol.":[154],"Cells":[155],"incubated":[157,338],"overnight":[158],"with":[159,190,222,238,339,377,541,560],"varied":[160],"concentrations":[161,485,525],"FTY720,":[163,378],"azacitidine,":[164],"idarubicin,":[165],"cytarabine,":[166],"or":[167,457],"drugs":[168,463],"combination.":[170],"After":[171],"incubation,":[172],"analyzed":[175],"by":[176,247],"colorimetric":[177],"assay.":[178],"Percent":[179],"cytotoxicity":[180,218,468,623,678,689],"was":[181,204,306,380,420,428,460],"estimated":[182,205,270,287,362],"proportion":[185],"light":[187,248],"absorbance":[188],"compared":[189,396],"blank":[191],"media":[192],"untreated":[194],"control":[195],"cells.":[196,548,681,692],"Inhibitory":[197],"concentration":[198],"50%":[200],"(IC50)":[203],"GraphPad":[207],"Prism":[208],"software,":[209],"version":[210],"6.0.":[211],"Flow":[212,315,673,684],"cytometry":[213,316],"confirmation":[216],"also":[220,337],"antibodies":[223,239],"against":[224,240],"Annexin":[225],"V":[226],"propidium":[228],"iodide.":[229],"For":[230],"estimation":[231],"expression,":[234],"ELISA":[237,386],"SET\u03b1":[241,391,603],"SET\u00df":[243,393,605],"quantified":[245],"measurements":[246],"absorption.":[249],"RESULTS:":[250],"FTY720inhibits":[251],"growth":[252],"independently":[256],"both":[258,323],"samples.":[263],"THP-1":[266,658,668],"line,":[268,285,357,416],"IC50":[272,289,305],"FTY720":[274,342,439,510,583,656,666,677,688],"3.4":[277],"\u03bcM":[278,308],"(Figure":[279,333],"1).":[280,352],"HL-60":[283,355,680,691],"2.5":[292],"\u03bcM.":[293],"had":[300],"similar":[301],"findings.":[302],"mean":[304],"3.24":[307],"(SD":[309],"=":[310,313],"1.32,":[311],"n":[312],"8).":[314],"tested":[318],"confirmed":[320],"induction":[321],"apoptosis":[324],"death":[327],"within":[328],"3-hour":[330],"time":[331],"frame":[332],"2).":[334,410],"Samples":[335],"combination":[340,376],"conventional":[344],"cytotoxic":[345,442,452],"chemotherapeutic":[346],"agents":[347],"used":[348,609,621],"(Table":[351,409],"following":[359],"IC50s":[360],"these":[364,565,585,637],"drugs:":[365],"idarubicin":[366],"(0.02":[367],"\u03bcM);":[368,371],"cytarabine":[369],"(0.6":[370],"azacitidine":[372],"(5.7":[373],"\u03bcM).":[374],"there":[379],"no":[381,455],"appreciable":[382],"change.":[383],"Results":[384],"showed":[387],"measurable":[388],"but":[389],"low":[390],"levels,":[394,613],"when":[395,462],"known":[399],"positive":[400],"control,":[401],"Ramos":[403],"line":[405],"Burkitt's":[407],"lymphoma":[408],"MV-4":[413],"SET\u03b1/\u00df":[418],"ratio":[419,427,631],"0.096.":[421],"cells,":[424,521],"\u03b1/\u00df":[426,544,630],"measured":[429],"at":[430],"0.063.":[431],"DISCUSSION:":[432],"These":[433],"support":[435],"assertion":[437],"agent":[443,476],"This":[446],"effect":[447,459],"independent":[449],"other":[451,550],"agents,":[453],"additive":[456],"synergistic":[458],"demonstrated":[461],"combined.":[465],"micromolar":[467],"poses":[469],"challenges":[470],"adoption":[473],"active":[479],"serum":[484],"currently":[487],"prescribed":[488],"doses":[489],"sclerosis":[492],"have":[493,539,557,596],"shown":[495],"achieve":[497],"only":[498],"nanomolar":[499],"concentrations.":[500],"It":[501],"notable":[503],"volume":[506],"distribution":[508],"very":[512],"high":[513,553],"90%":[516],"concentrated":[518],"blood":[520],"so":[522],"actual":[523],"may":[526],"substantially":[528],"higher.":[529],"Our":[530],"work":[531],"not":[533,568],"yielded":[534],"same":[536],"results":[537,566],"others":[538],"reported":[540],"increased":[542],"ratios":[545,556],"types,":[552],"alpha":[555],"associated":[559],"higher":[561],"activity;":[563],"thus,":[564],"would":[567],"suggestive":[570],"such":[572],"role":[574],"Despite":[577],"our":[578],"findings,":[579],"merits":[587],"further":[588],"investigation":[589],"into":[590],"We":[595,634],"recently":[597],"flow":[599],"cytometric":[600,674,685],"assay":[601],"can":[607],"quantify":[611],"plan":[616],"analyze":[618],"patient":[619],"help":[626],"identify":[627],"hope":[635],"will":[639],"establish":[640],"targets":[645],"development":[648],"Figure":[651,661,671,682],"1":[652],"curve":[654,664],"(n=3)":[660,670],"1.":[662],"2":[672],"analysis":[675,686],"2.":[683],"Disclosures":[693],"Rao:":[694],"Gilead,":[695],"Inc.:":[696],"Employment.":[697]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-06-05T00:00:00"}